Baek et al.[19] reported that the median interval from diagnosis to BM development in patients with stage IV NSCLC (predominantly ns‐NSCLC, 84.6%) did not significantly differ between EGFR‐mutant and wild‐type groups (13.4 vs 8.8 months, p = 0.229). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.